drugset / Trial / NCT00894114
A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)
RandomizedParallel-groupDouble-blindPrevention
Summary
This study is designed to determine whether patients previously primed with Ad5 of MRKAd5 HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with MKRAd5 HIV-1 gag vaccine.
Timeline
- Start
- 2003-05
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALVAC-HIV | Vaccine | — | Intramuscular |
| Subject | V520 | Vaccine | 1 ml | Intramuscular |